-inc-logo-1200x675.png){kind=logo}
WuXi Biologics (Cayman) (OTCMKTS:WXXWY – Get Free Report) is projected to post its resultson Tuesday, August 25th. Analysts expect WuXi Biologics (Cayman) to post earnings of $0.1330 per share and revenue of $1.6950 billion for the quarter.
WuXi Biologics (Cayman) Stock Performance
Shares of OTCMKTS:WXXWY opened at $12.91 on Monday. WuXi Biologics has a one year low of $7.30 and a one year high of $13.00. The business’s 50-day simple moving average is $9.83 and its 200 day simple moving average is $9.28.
WuXi Biologics (Cayman) Company Profile
WuXi Biologics (Cayman) Inc, trading OTC as WXXWY, is a global contract research, development and manufacturing organization (CDMO) specializing in biologics. Founded as a spin-out from WuXi AppTec and incorporated in the Cayman Islands in 2017, the company offers end-to-end support across the biologics value chain. Its service portfolio encompasses discovery biology, analytical development, process chemistry and large-scale manufacturing for therapeutic proteins and antibodies.
The firm’s core offerings include the development of monoclonal antibodies, recombinant proteins and cell and gene therapy vectors.
Read More
- Five stocks we like better than WuXi Biologics (Cayman)
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for WuXi Biologics (Cayman) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi Biologics (Cayman) and related companies with MarketBeat.com's FREE daily email newsletter.
